Advertisement

Digestive Diseases and Sciences

, Volume 57, Issue 8, pp 2233–2240 | Cite as

Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma

  • David E. KleinerEmail author
  • David Berman
Case Report

Introduction

Ipilimumab is a fully human, monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 (CTLA-4), an immune checkpoint molecule that negatively regulates T-cell activation [1]. It is hypothesized that CTLA-4 blockade can break peripheral tolerance to tumor antigens, promoting an antitumor immune response [2]. Ipilimumab has shown durable objective responses and encouraging long-term survival in phase II trials involving patients with metastatic melanoma [3, 4, 5, 6]. In a phase III, randomized controlled trial, ipilimumab monotherapy demonstrated a statistically significant improvement in overall survival in previously treated patients with metastatic melanoma [7]. Recently, the results of another phase III trial with ipilimumab were reported for previously untreated patients with metastatic melanoma, which showed a statistically significant improvement in overall survival for ipilimumab plus dacarbazine compared with dacarbazine alone [8]. The treatment-related...

Keywords

Ipilimumab Drug-induced hepatitis CTLA-4 Immunosuppressive therapy Metastatic melanoma 

Abbreviations

AE

Adverse event

ALT

Alanine aminotransferase

AP

Alkaline phosphatase

AST

Aspartate aminotransferase

CTLA-4

Cytotoxic T-lymphocyte antigen-4

ULN

Upper limit of normal

Notes

Acknowledgments

Editorial and writing assistance was provided by StemScientific, funded by Bristol-Myers Squibb Co. This research was supported in part by the Intramural Research Program of the US National Institutes of Health (National Cancer Institute).

Conflict of interest

David E. Kleiner: No financial, professional or personal conflicts of interest exist with respect to this work. David Berman is an employee of Bristol-Myers Squibb Company and discloses ownership of equity in the company.

References

  1. 1.
    Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008;26:5275–5283.PubMedCrossRefGoogle Scholar
  2. 2.
    Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008;13:2–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009;15:5591–5598.PubMedCrossRefGoogle Scholar
  4. 4.
    Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155–164.PubMedCrossRefGoogle Scholar
  5. 5.
    O’Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with previously treated, advanced melanoma: a multicenter, single-arm phase II study. Ann Oncol. 2010;21:1712–1717.PubMedCrossRefGoogle Scholar
  6. 6.
    Maio M, Lebbé C, Neyns B, et al. Three-Year Survival Rates for Patients with Advanced Melanoma Who Received Ipilimumab at 10 mg/kg in Phase II Trials [Abstract]. In: Presented at the XIV annual meeting of the perspectives in melanoma, 2010 September 17–18, Amsterdam, The Netherlands. 2010.Google Scholar
  7. 7.
    Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.PubMedCrossRefGoogle Scholar
  8. 8.
    Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–2526. doi: 10.1056/NEJMoa1104621.Google Scholar
  9. 9.
    Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007;12:864–872.PubMedCrossRefGoogle Scholar
  10. 10.
    Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol. 2010;37:533–546.PubMedCrossRefGoogle Scholar
  11. 11.
    Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockades in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372–8377.PubMedCrossRefGoogle Scholar
  12. 12.
    Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043–6053.PubMedCrossRefGoogle Scholar
  13. 13.
    Qiu D, Wang Q, Wang H, et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol. 2011;54:340–347.PubMedCrossRefGoogle Scholar
  14. 14.
    Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver Injury. Clin Pharmacol Ther. 2011;89:806–815.PubMedCrossRefGoogle Scholar
  15. 15.
    Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56:958–976.PubMedCrossRefGoogle Scholar
  16. 16.
    Suriawinata AA, Thung SN. Acute and chronic hepatitis. Semin Diagn Pathol. 2006;23:132–148.PubMedCrossRefGoogle Scholar
  17. 17.
    Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360:2758–2769.PubMedCrossRefGoogle Scholar
  18. 18.
    Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354:54–66.PubMedCrossRefGoogle Scholar
  19. 19.
    Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology. 2011;54:931–939.PubMedCrossRefGoogle Scholar
  20. 20.
    Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010;10:11–21.PubMedGoogle Scholar
  21. 21.
    Sulz MC, Gerlach TJ. Autoimmune hepatitis. Ther Umsch. 2011;68:189–194.PubMedCrossRefGoogle Scholar
  22. 22.
    Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC (Outside the USA) 2012

Authors and Affiliations

  1. 1.Laboratory of PathologyNational Cancer InstituteBethesdaUSA
  2. 2.Research and Development–Global Clinical ResearchBristol-Myers Squibb CompanyPrincetonUSA

Personalised recommendations